-
With more employers recognizing the real costs of overweight employees and getting behind weight management programs, why do the headlines continue to scream that Americans are the fattest people in the world? Does anybody know the secret to successful, long-term weight loss? In a series of interviews, the experts shared their thoughts on what has worked and what hasnt in their own workplace efforts.
-
Often overlooked, older HIV patients provide a glimpse into the future of the AIDS epidemic in nations where antiretroviral therapy is readily available. AIDS Alert has asked HIV clinicians, researchers, and patients to discuss how these older patients might help us predict the future of the epidemic as the population of HIV-infected people older than 50 increases.
-
-
-
In a ground-breaking study published in the fall/winter issue of Advances in Mind-Body Medicine, a six-week program based upon Group Empowered Drumming demonstrated not only reduced burnout in long-term care workers, but also reduced Total Mood Disturbance by 46%.
-
Ergonomics is more than a way to lift patients. As Butler (PA) Memorial Hospital found, it can lift morale and employee satisfaction as well.
-
Root cause analysis, long a popular tool for quality improvement initiatives, holds tremendous promise for occupational health professionals seeking to improve their disability management programs, says Jennifer Christian,MD, president and chief medical officer of Webility Corp. in Wayland, MA.
-
Mirroring an overall trend in health care quality, employee safety increasingly is taking center stage for occupational health nurses, say the experts. And this trend is growing in two parallel directions: an expanding role for current occ-health nursing positions, as well as potential new job opportunities.
-
Imatinib was administered to newly diagnosed patients with chronic-phase myelogenous leukemia at a dose (800 mg daily) double what is commonly prescribed. Cytogenetic and molecular responses were significantly better than observed in an historical cohort of similar patients treated with 400 mg daily.
-
In a phase II trial of cetuximab (Erbitux) given once weekly to patients with advanced colorectal cancer who had failed prior irinotecan treatment, a modest response rate was observed and the toxicity profile was shown to be manageable.
